The partnership will enable Viroclinics to benefit from the experience of an established financial investor in the healthcare industry. The transaction paved the way for an exit of Erasmus MC, the founding institute. Viroclinics intends to continue its collaboration with the Erasmus MC, department of viroscience, and co-develop new laboratory services in virology.
"With Gilde as new shareholder, we have secured access to capital for the company's mid- and long-term strategic goals," said Bob van Gemen, CEO of Viroclinics. “This will enable us to expand our service offering while building on our current strengths. The new partnership with Gilde has neither implications for the management nor organizational structure of the company.”
